| Literature DB >> 29476231 |
Karla Pelivan1, Lisa M Frensemeier2, Uwe Karst2, Gunda Koellensperger3, Petra Heffeter4,5, Bernhard K Keppler1,5, Christian R Kowol6,7.
Abstract
Clinical failure of novel drugs is often related to their rapid metabolism and excretion. This highlights the importance of elucidation of their pharmacokinetic profile already at the preclinical stage of drug development. Triapine, the most prominent representative of α-N-Entities:
Keywords: Drug metabolism; Electrochemical oxidation; In vivo metabolism; Microsomes; Thiosemicarbazones
Mesh:
Substances:
Year: 2018 PMID: 29476231 PMCID: PMC5849672 DOI: 10.1007/s00216-018-0889-x
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Scheme 1The metabolic pathways of Triapine [18]
Scheme 2Molecular structures of the investigated α-N-heterocyclic thiosemicarbazones (1–10) and Triapine
Fig. 1Mass voltammogram of thiosemicarbazone 5
Fig. 2Mass voltammogram of thiosemicarbazone 7
Metabolites of compound 5 detected by EC/MS
| Modification | Sum formula | Detected | Theoretical | Rel. deviation [ppm] | Metabolic reaction |
|---|---|---|---|---|---|
| [M + H]+ | C11H18N5S | 252.12747 | 252.12774 | 1.08 | – |
| [M–N–2xCH3]+ | C9H11N4S | 207.06998 | 207.06989 | 0.42 | |
| [M–2H + H]+ | C11H16N5S | 250.11211 | 250.11209 | 0.07 | Dehydrogenation |
| [M–4H + H]+ | C11H14N5S | 248.09650 | 248.09644 | 0.23 | Dehydrogenation |
| [M + O + H]+ | C11H18N5SO | 268.12256 | 268.12266 | 0.36 | Hydroxylation |
| [M + O–2H + H]+ | C11H16N5SO | 266.10681 | 266.10701 | 0.74 | Hydroxylation/ |
| [M + O–4H + H]+ | C11H14N5SO | 264.09116 | 264.09136 | 0.75 | Hydroxylation/ |
| [M–S + O + H]+ | C11H18N5O | 236.15062 | 236.15059 | 0.14 | Desulfuration |
| [M–S + O–2H + H]+ | C11H16N5O | 234.13492 | 234.13494 | 0.07 | Desulfuration/ |
| [M–S + H]+ | C11H18N5 | 220.15564 | 220.15567 | 0.15 | Desulfuration |
| [M–S–2H + H]+ | C11H16N5 | 218.14020 | 218.14002 | 0.82 | Desulfuration/ |
| [M–CH2 + H]+ | C10H16N5S | 238.11206 | 238.11209 | 0.14 | Demethylation |
| [M–CH2–2H + H]+ | C10H14N5S | 236.09641 | 236.09644 | 0.14 | Demethylation/ |
| [M–2xCH2 + H]+ | C9H14N5S | 224.09621 | 224.09644 | 1.04 | Demethylation* |
| [M–2xCH2–2H + H]+ | C9H12N5S | 222.08055 | 222.08079 | 1.09 | Demethylation/ |
| [M–3xCH2–2H + H]+ | C8H10N5S | 208.06487 | 208.06514 | 1.31 | Demethylation/ |
| [2M–2H + H]+ | C22H33N10S2 | 501.23254 | 501.23256 | 0.04 | Disulfide formation |
| [2M–4H + H]+ | C22H31N10S2 | 499.21692 | 499.21691 | 0.02 | Disulfide formation/ |
*Observed after electrochemical oxidation only via LC-HRMS, but not via EC-HRMS
Metabolites of compound 7 detected by EC/MS
| Modification | Sum formula | Detected | Theoretical | Rel. deviation [ppm] | Metabolic reaction |
|---|---|---|---|---|---|
| [M + H]+ | C8H11N4S | 195.06987 | 195.06989 | 0.12 | – |
| [M–NH2]+ | C8H8N3S | 178.04340 | 178.04334 | 0.31 | |
| [M + O + H]+ | C8H11N4SO | 211.06494 | 211.06481 | 0.62 | Hydroxylation |
| [M + O–2H + H]+ | C8H9N4SO | 209.04904 | 209.04916 | 0.57 | Hydroxylation/ |
| [M–S + H]+ | C8H11N4 | 163.09796 | 163.09782 | 0.84 | Desulfuration |
| [M–S–2H + H]+ | C8H9N4 | 161.08232 | 161.08217 | 0.91 | Desulfuration/ |
| [M–CH2–2H + H]+ | C7H7N4S | 179.03848 | 179.03859 | 0.63 | Demethylation/ |
| [2M–2H + H]+ | C16H19N8S2 | 387.11694 | 387.11686 | 0.21 | Disulfide formation |
*Observed after electrochemical oxidation only via LC-HRMS, but not via EC-HRMS
Fig. 3LC-HRMS analysis of terminally monomethylated Triapine (1) and its main dehydrogenated metabolite after electrochemical oxidation at + 1800 mV vs. Pd/H2
Fig. 4LC-HRMS analysis of 2-acetylpyridine N,N-dimethyl thiosemicarbazone (9) and its main metabolites after electrochemical oxidation at + 1800 mV vs. Pd/H2
Metabolic reactions observed for the investigated thiosemicarbazones via LC-HRMS after electrochemical oxidation at + 1800 mV vs. Pd/H2 with the intensities of the obtained metabolites (✓: > 106 AU, ~: 105–106 AU, x: < 104 AU)
| Modification | Metabolic reaction |
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| [M–2H + H]+ | Dehydrogenation |
|
|
|
|
|
|
|
|
|
|
| [M + O + H]+ | Hydroxylation |
|
|
|
|
|
|
|
|
|
|
| [M + O–2H + H]+ | Hydroxylation/Dehydrogenation |
|
|
|
|
|
|
|
|
|
|
| [M–S + H]+ | Desulfuration C (Amidrazone) |
|
|
|
|
|
|
|
|
|
|
| [M–S–2H + H]+ | Desulfuration/Dehydrogenation |
|
|
|
|
|
|
|
|
|
|
| [M–S + O + H]+ | Desulfuration C=O (Semicarbazone) |
|
|
|
|
|
|
|
|
|
|
| [M–S + O–2H + H]+ | Desulfuration/Dehydrogenation |
|
|
|
|
|
|
|
|
|
|
Demethylation of the investigated thiosemicarbazones detected via LC-HRMS after electrochemical oxidation at + 1800 mV vs. Pd/H2 with the intensities of the obtained metabolites (✓: > 106 AU, ~: 105–106 AU, x: < 104 AU; the gray areas represent metabolic reactions which are not possible)
Fig. 5LC-HRMS analysis of the tetramethylated Triapine derivative 5 and some of its main metabolites after cell-free incubations with HLM
Metabolic reactions observed for the investigated thiosemicarbazones via LC-HRMS after cell-free incubations with HLM with the intensities of the obtained metabolites (✓: > 106 AU, ~: 105–106 AU, x: < 104 AU)
| Modification | Metabolic reaction |
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| [M–2H + H]+ | Dehydrogenation |
|
|
|
|
|
|
|
|
|
|
| [M + O + H]+ | Hydroxylation |
|
|
|
|
|
|
|
|
|
|
| [M + O–2H + H]+ | Hydroxylation/Dehydrogenation |
|
|
|
|
|
|
|
|
|
|
| [M–S + H]+ | Desulfuration C (Amidrazone) |
|
|
|
|
|
|
|
|
|
|
| [M–S–2H + H]+ | Desulfuration/Dehydrogenation |
|
|
|
|
|
|
|
|
|
|
| [M–S + O + H]+ | Desulfuration C=O (Semicarbazone) |
|
|
|
|
|
|
|
|
|
|
| [M–S + O–2H + H]+ | Desulfuration/Dehydrogenation |
|
|
|
|
|
|
|
|
|
|
Demethylation of the investigated thiosemicarbazones detected via LC-HRMS after cell-free incubations with HLM with the intensities of the obtained metabolites (✓: > 106 AU, ~: 105–106 AU, x: < 104 AU; the gray areas represent metabolic reactions which are not possible)
*The demethylated/dehydrogenated metabolite is not a product of the simply demethylated metabolite
Fig. 6LC-MS/MS spectra and structural elucidation of the hydroxylation as well as semicarbazone formation of the 3-dimethylaminopyridine Triapine derivative 4 after incubation with human liver microsomes
Fig. 7LC-MS/MS spectra and structural elucidation of the dehydrogenated metabolite of the 3-dimethylaminopyridine Triapine derivative 4 after incubation with human liver microsomes. In addition, also the dehydrogenated semicarbazone and dehydrogenated hydroxylated metabolites are depicted
Scheme 3Overview of the metabolic pathways of the 3-dimethylaminopyridine Triapine derivative 4 elucidated by LC-HRMS after incubation with cell-free human liver microsomes
Scheme 4Overview of the in vivo metabolic pathways of 5 (main metabolites are marked with a circle; metabolites observed with microsomes but not in vivo are crossed out)
Fig. 8Relative quantification of metabolites 1–23 of compound 5 in serum/liver/kidney/urine samples of mice